E-submission
Search
- Page Path
- HOME > Search
Original Article
- Evaluation of Pathologic Complete Response in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Experience in a Single Institution over a 10-Year Period
- Misun Choi, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im, Seok Jin Nam, Soo Youn Cho, Eun Yoon Cho
- J Pathol Transl Med. 2017;51(1):69-78. Published online December 25, 2016
- DOI: https://doi.org/10.4132/jptm.2016.10.05
- 10,621 View
- 266 Download
- 21 Web of Science
- 20 Crossref
-
Abstract
PDF - Background
Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) has been associated with favorable clinical outcome in breast cancer patients. However, the possibility that the prognostic significance of pCR differs among various definitions has not been established. Methods: We retrospectively evaluated the pathologic response after NAC in 353 breast cancer patients and compared the prognoses after applying the following different definitions of pCR: ypT0/is, ypT0, ypT0/is ypN0, and ypT0 ypN0. Results: pCR was significantly associated with improved distant disease-free survival (DDFS) regardless of the definition (ypT0/is, p = .002; ypT0, p = .008; ypT0/is ypN0, p < .001; ypT0 ypN0, p = .003). Presence of tumor deposits of any size in the lymph nodes (LNs; ypN ≥ 0(i+)) was associated with worse DDFS (ypT0 ypN0 vs ypT0 ypN ≥ 0(i+), p = .036 and ypT0/is ypN0 vs ypT0/is ypN ≥ 0(i+), p = .015), and presence of isolated tumor cells was associated with decreased overall survival (OS; ypT0/is ypN0 vs ypT0/is ypN0(i+), p = .013). Residual ductal carcinoma in situ regardless of LN status showed no significant difference in DDFS or OS (DDFS: ypT0 vs ypTis, p = .373 and ypT0 ypN0 vs ypTis ypN0, p = .462; OS: ypT0 vs ypTis, p = .441 and ypT0 ypN0 vs ypTis ypN0, p = .758). In subsequent analysis using ypT0/is ypN0, pCR was associated with improved DDFS and OS in triple-negative tumors (p < .001 and p = .003, respectively). Conclusions: Based on our study results, the prognosis and rate of pCR differ according to the definition of pCR and ypT0/is ypN0 might be considered a more preferable definition of pCR. -
Citations
Citations to this article as recorded by
- Association of residual ductal carcinoma in situ with breast cancer treatment outcomes after neoadjuvant chemotherapy according to hormone receptor status
Eunju Shin, Tae-Kyung Yoo, Jisun Kim, Il Yong Chung, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Sae Byul Lee
Discover Oncology.2024;[Epub] CrossRef - Pathology after neoadjuvant treatment – How to assess residual disease
Giuseppe Viale, Nicola Fusco
The Breast.2022; 62: S25. CrossRef - Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC)
Nicola Fusco, Antonio Rizzo, Leopoldo Costarelli, Alfredo Santinelli, Bruna Cerbelli, Cristian Scatena, Ettore Macrì, Francesca Pietribiasi, Giulia d’Amati, Anna Sapino, Isabella Castellano
Pathologica.2022; 114(2): 104. CrossRef - Pathological complete response as a surrogate to improved survival in human epidermal growth factor receptor-2-positive breast cancer: systematic review and meta-analysis
Matthew G. Davey, Ferdia Browne, Nicola Miller, Aoife J. Lowery, Michael J. Kerin
BJS Open.2022;[Epub] CrossRef - Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years
Lisi M. Dredze, Michael Friger, Samuel Ariad, Michael Koretz, Bertha Delgado, Ruthy Shaco-Levy, Margarita Tokar, Michael Bayme, Ravit Agassi, Maia Rosenthal, Victor Dyomin, Olga Belochitski, Shai Libson, Tamar Mizrahi, David B. Geffen
Breast Cancer Research and Treatment.2022; 193(3): 597. CrossRef - “No Ink on Tumor” in Breast-Conserving Surgery after Neoadjuvant Chemotherapy
Giulia Atzori, Marco Gipponi, Chiara Cornacchia, Raquel Diaz, Marco Sparavigna, Maurizio Gallo, Tommaso Ruelle, Federica Murelli, Simonetta Franchelli, Francesca Depaoli, Daniele Friedman, Piero Fregatti
Journal of Personalized Medicine.2022; 12(7): 1031. CrossRef - Machine Learning Models and Multiparametric Magnetic Resonance Imaging for the Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer
Carmen Herrero Vicent, Xavier Tudela, Paula Moreno Ruiz, Víctor Pedralva, Ana Jiménez Pastor, Daniel Ahicart, Silvia Rubio Novella, Isabel Meneu, Ángela Montes Albuixech, Miguel Ángel Santamaria, María Fonfria, Almudena Fuster-Matanzo, Santiago Olmos Antó
Cancers.2022; 14(14): 3508. CrossRef - Applying artificial intelligence technology to assist with breast cancer diagnosis and prognosis prediction
Meredith A. Jones, Warid Islam, Rozwat Faiz, Xuxin Chen, Bin Zheng
Frontiers in Oncology.2022;[Epub] CrossRef - Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy
Ina Jani, Ricardo R Lastra, Katherine S Brito, Chuanhong Liao, Isabel Lazo, Nita Karnik Lee, S Diane Yamada, Katherine C Kurnit
International Journal of Gynecologic Cancer.2021; 31(6): 852. CrossRef - Application of neoadjuvant chemotherapy combined with anlotinib in occult breast cancer: A case report and review of literature
Yu Zhang, Di Wu, Bo Zhao, Xue-Liang Tian, Tian-Cheng Yao, Feng Li, Wei-Fang Liu, Ai-Ping Shi
World Journal of Clinical Cases.2021; 9(4): 919. CrossRef - Pathologic Complete Response and Its Impact on Breast Cancer Recurrence and Patient’s Survival after Neoadjuvant Therapy: A Comprehensive Meta-Analysis
Hui Liu, Liqiong Lv, Hui Gao, Ming Cheng, Tao Huang
Computational and Mathematical Methods in Medicine.2021; 2021: 1. CrossRef - Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and Survival
K. Wimmer, M. Bolliger, Z. Bago-Horvath, G. Steger, D. Kauer-Dorner, R. Helfgott, C. Gruber, F. Moinfar, M. Mittlböck, F. Fitzal
Annals of Surgical Oncology.2020; 27(5): 1700. CrossRef - Predictive factors for omitting lymphadenectomy in patients with node‐positive breast cancer treated with neo‐adjuvant systemic therapy
Sergi Fernandez‐Gonzalez, Catalina Falo, Maria J. Pla, Paula Verdaguer, Diana Nuñez, Anna Guma, Teresa Soler, Andrea Vethencourt, Silvia Vázquez, Maria Eulalia Fernandez‐Montoli, Miriam Campos, Sonia Pernas, Miguel Gil, Jordi Ponce, Amparo Garcia‐Tejedor
The Breast Journal.2020; 26(5): 888. CrossRef - Is There a Role for Post-Mastectomy Radiotherapy for T1-2N1 Breast Cancers With Node-Positive Pathology After Patients Become Node-Negative Pathology Following Neoadjuvant Chemotherapy?
Qian Wang, Jingjing Zhao, Xiaowei Han, Puchun Er, Xiangying Meng, Jinyan Shi, Huiru Sun, Jingyang Zhu, Li Zhu, Shikai Wu, Wencheng Zhang, Bing Sun
Frontiers in Oncology.2020;[Epub] CrossRef - Prognostic role of microRNA 182 and microRNA 18a in locally advanced triple negative breast cancer
Rajat Bajaj, Rupal Tripathi, T. S. Sridhar, Aruna Korlimarla, Kumardeep Dutta Choudhury, Moushumi Suryavanshi, Anurag Mehta, Dinesh Chandra Doval, Elda Tagliabue
PLOS ONE.2020; 15(11): e0242190. CrossRef - Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis
Min Huang, Joyce O'Shaughnessy, Jing Zhao, Amin Haiderali, Javier Cortés, Scott D. Ramsey, Andrew Briggs, Peter Hu, Vassiliki Karantza, Gursel Aktan, Cynthia Z. Qi, Chenyang Gu, Jipan Xie, Muhan Yuan, John Cook, Michael Untch, Peter Schmid, Peter A. Fasch
Cancer Research.2020; 80(24): 5427. CrossRef - Multiparametric MR imaging to assess response following neoadjuvant systemic treatment in various breast cancer subtypes: Comparison between different definitions of pathologic complete response
G Santamaría, X Bargalló, S Ganau, I Alonso, M Muñoz, M Mollà, PL Fernández, A Prat
European Journal of Radiology.2019; 117: 132. CrossRef - Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy
Reshu Agarwal, Arun Philip, Keechilat Pavithran, Anupama Rajanbabu, Gaurav Goel, DK Vijaykumar
Indian Journal of Cancer.2019; 56(3): 228. CrossRef - Application of neoadjuvant chemotherapy in occult breast cancer
Haisong Yang, Ling Li, Mengmeng Zhang, Shiyong Zhang, Shu Xu, Xiaoxia Ma
Medicine.2017; 96(40): e8200. CrossRef - Wnt7a Deficiency Could Predict Worse Disease-Free and Overall Survival in Estrogen Receptor-Positive Breast Cancer
Kijong Yi, Kyueng-Whan Min, Young Chan Wi, Yeseul Kim, Su-Jin Shin, Min Sung Chung, Kiseok Jang, Seung Sam Paik
Journal of Breast Cancer.2017; 20(4): 361. CrossRef
- Association of residual ductal carcinoma in situ with breast cancer treatment outcomes after neoadjuvant chemotherapy according to hormone receptor status
First
Prev
